William P.  Quinn net worth and biography

William Quinn Biography and Net Worth

Willie Quinn, Chief Financial Officer, joined Bolt Biotherapeutics in 2020. Prior to joining Bolt, Willie served as the chief financial officer and senior vice president corporate development of Sunesis Pharmaceuticals (SNSS). He led Sunesis’ fundraising and partnering efforts, raising over $60 million in public funding and signing multiple deals with industry partners. Prior to Sunesis he led Bullet Biotechnology, a company that he co-founded to develop cancer immunotherapies based on technology from Stanford University, as chief executive officer. Willie was instrumental in establishing the infrastructure at Jazz Pharmaceuticals (JAZZ), where he was one of the first employees and worked for more than eight years. He rose to head of corporate development, also overseeing strategy and investor relations, helping Jazz transform from a private startup to a public, profitable specialty pharmaceutical company. Before Jazz, Willie was the chief financial officer and chief operating officer of Novation Biosciences, a biotechnology software company that was acquired by Agilent Technologies. He currently serves on the board of A Foundation Building Strength, a nonprofit with a mission to find treatments for Nemaline Myopathy. Willie earned an M.A. and B.A. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.

What is William P. Quinn's net worth?

The estimated net worth of William P. Quinn is at least $17,985.38 as of December 6th, 2023. Mr. Quinn owns 28,772 shares of Bolt Biotherapeutics stock worth more than $17,985 as of December 3rd. This net worth estimate does not reflect any other investments that Mr. Quinn may own. Additionally, Mr. Quinn receives an annual salary of $610,800.00 as CFO at Bolt Biotherapeutics. Learn More about William P. Quinn's net worth.

How old is William P. Quinn?

Mr. Quinn is currently 53 years old. There are 2 older executives and no younger executives at Bolt Biotherapeutics. Learn More on William P. Quinn's age.

What is William P. Quinn's salary?

As the CFO of Bolt Biotherapeutics, Inc., Mr. Quinn earns $610,800.00 per year. Learn More on William P. Quinn's salary.

How do I contact William P. Quinn?

The corporate mailing address for Mr. Quinn and other Bolt Biotherapeutics executives is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. Bolt Biotherapeutics can also be reached via phone at 650-665-9295 and via email at [email protected]. Learn More on William P. Quinn's contact information.

Has William P. Quinn been buying or selling shares of Bolt Biotherapeutics?

William P. Quinn has not been actively trading shares of Bolt Biotherapeutics in the last ninety days. Most recently, on Tuesday, December 12th, William P. Quinn bought 7,500 shares of Bolt Biotherapeutics stock. The stock was acquired at an average cost of $0.95 per share, with a total value of $7,125.00. Following the completion of the transaction, the chief financial officer now directly owns 36,272 shares of the company's stock, valued at $34,458.40. Learn More on William P. Quinn's trading history.

Are insiders buying or selling shares of Bolt Biotherapeutics?

In the last twelve months, Bolt Biotherapeutics insiders bought shares 2 times. They purchased a total of 10,000 shares worth more than $9,075.00. The most recent insider tranaction occured on December, 12th when CFO William P Quinn bought 7,500 shares worth more than $7,125.00. Insiders at Bolt Biotherapeutics own 30.9% of the company. Learn More about insider trades at Bolt Biotherapeutics.

Information on this page was last updated on 12/12/2023.

William P. Quinn Insider Trading History at Bolt Biotherapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2023Buy7,500$0.95$7,125.0036,272View SEC Filing Icon  
12/6/2023Buy2,500$0.78$1,950.0028,772View SEC Filing Icon  
6/6/2023Buy1,829$1.18$2,158.2226,272View SEC Filing Icon  
12/8/2021Buy5,000$4.71$23,550.00View SEC Filing Icon  
12/6/2021Buy35$4.64$162.40View SEC Filing Icon  
6/4/2021Buy1,221$16.65$20,329.65View SEC Filing Icon  
2/9/2021Buy1,200$20.00$24,000.00
See Full Table

William P. Quinn Buying and Selling Activity at Bolt Biotherapeutics

This chart shows William P Quinn's buying and selling at Bolt Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bolt Biotherapeutics Company Overview

Bolt Biotherapeutics logo
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $0.63
Low: $0.63
High: $0.65

50 Day Range

MA: $0.63
Low: $0.56
High: $0.68

2 Week Range

Now: $0.63
Low: $0.54
High: $1.56

Volume

41,256 shs

Average Volume

118,823 shs

Market Capitalization

$23.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93